Journal
CORNEA
Volume 30, Issue 1, Pages 60-66Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/ICO.0b013e3181e458c5
Keywords
bevacizumab; corneal neovascularization; lipid keratopathy; subconjunctival injection; vascular endothelial growth factor (VEGF)
Categories
Funding
- Department of Medical Research at the National Taiwan University Hospital [NTUH 97-S831]
- National Taiwan University Hospital, Taipei, Taiwan
- National Science Council, the Executive Yuan, Taiwan [NSC 97-2314-B-002-085-MY3]
Ask authors/readers for more resources
Purpose: To determine the effects on corneal neovascularization (NV) and lipid deposition after subconjunctival injection of bevacizumab in patients who had NV associated with lipid keratopathy. Methods: A case interventional study enrolled 18 patients (18 eyes) with lipid keratopathy. We gave monthly subconjunctival injections of bevacizumab from 3 to 10 times during the follow-up period according to the clinical response. We evaluated the centricity, extent, and percentage of involved corneal surface (PICS) of the corneal NV; the density and PICS of the corneal lipid deposition; and best-corrected visual acuity before and after treatment. We analyzed the treatment effects using Wilcoxon and Student t tests. Results: After the treatment, the change in best-corrected visual acuity was less than 2 lines. The extent, centricity, and PICS of the corneal NV and the density and PICS of the corneal lipid deposition decreased significantly after treatment (P = 0.014/0.002/0.001 and 0.001/<0.001, respectively). No eyes had side effects. Conclusions: The effects of subconjunctival injection of bevacizumab in treating corneal NV associated with lipid deposition were significant in some patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available